NEW YORK (GenomeWeb News) – Shares in Accelr8 were up 13.17 percent, or $.27, at $2.32 in mid-afternoon trading after the company said it won a US patent that covers devices that use its OptiChem surface chemistry, including those for patient specimen collection and analytical products.
Accel8 said U.S. Patent 7,067,194 also covers coating variations not specifically included in prior patents.
Accelr8 previously licensed certain OptiChem applications to other companies in the biomedical industry. The firm is now developing its BACcelr8r rapid bacterial diagnostic system that will use OptiChem in its single-use analytical cassette.
In addition, Accelr8 said it plans to develop related disposable products for handling patient specimens prior to analysis.